Denali Therapeutics (DNLI) News Today → Democrats Push to Replace Dollar With Digital Coin, Control Currency. (From Monetary Gold) (Ad) Free DNLI Stock Alerts $20.70 +0.46 (+2.27%) (As of 12:39 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | seekingalpha.comDenali Therapeutics: MPS Treatment Program Continues With End Of 2024 DataMay 13, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Denali Therapeutics (DNLI)May 13, 2024 | americanbankingnews.comFY2024 Earnings Forecast for Denali Therapeutics Inc. Issued By Cantor Fitzgerald (NASDAQ:DNLI)May 13, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Expected to Earn Q2 2024 Earnings of ($0.62) Per ShareMay 13, 2024 | americanbankingnews.comB. Riley Comments on Denali Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:DNLI)May 13, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI) Increased by AnalystMay 12, 2024 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Price Target Cut to $22.00 by Analysts at Stifel NicolausMay 12, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI)May 12, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) to Post FY2028 Earnings of $1.74 Per Share, Wedbush ForecastsMay 11, 2024 | americanbankingnews.comHC Wainwright Comments on Denali Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:DNLI)May 10, 2024 | markets.businessinsider.comPositive Outlook for Denali Therapeutics: Accelerated Approval and Financial Strategy Strengthening Market PositionMay 10, 2024 | markets.businessinsider.comOptimistic Outlook for Denali Therapeutics: Buy Rating Affirmed Amidst Positive ERT Developments and Strong Pipeline ProgressMay 10, 2024 | marketbeat.comFY2028 EPS Estimates for Denali Therapeutics Inc. Cut by Analyst (NASDAQ:DNLI)Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Wedbush lowered their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued to investors on Wednesday, May 8th. Wedbush analyst L. Chico now expects that the company will posMay 10, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Denali Therapeutics Inc.'s FY2027 Earnings (NASDAQ:DNLI)May 9, 2024 | finance.yahoo.comDenali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)May 9, 2024 | marketbeat.comHC Wainwright Equities Analysts Increase Earnings Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI)Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at HC Wainwright lifted their FY2027 EPS estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. HC Wainwright analyst A. Fein now forecasts that the cMay 9, 2024 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Trading Up 11.6% on Strong EarningsMay 8, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Given New $30.00 Price Target at WedbushWedbush dropped their price target on Denali Therapeutics from $31.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday.May 8, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Stock Price Up 11.6% on Better-Than-Expected EarningsDenali Therapeutics (NASDAQ:DNLI) Trading Up 11.6% After Strong EarningsMay 8, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Denali Therapeutics (NASDAQ:DNLI)HC Wainwright reissued a "buy" rating and issued a $95.00 target price on shares of Denali Therapeutics in a report on Wednesday.May 8, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Issues Quarterly Earnings ResultsDenali Therapeutics (NASDAQ:DNLI - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same period in the prior year, the company posted ($0.80) earnings per share.May 7, 2024 | finance.yahoo.comDenali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic ShiftsMay 7, 2024 | finance.yahoo.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 7, 2024 | globenewswire.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 2, 2024 | markets.businessinsider.comBuy Recommendation for DNLI: Promising Safety and Efficacy of Denali’s ALS Drug DNL343May 1, 2024 | globenewswire.comDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialApril 29, 2024 | finance.yahoo.comIs There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?April 27, 2024 | marketbeat.com324,829 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by abrdn plcabrdn plc bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 324,829 shares of the company's stock, valued at approximately $6,971,000. abrdn plc owned approximately 0.23% of Denali TApril 25, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Hits New 52-Week Low at $14.56Denali Therapeutics (NASDAQ:DNLI) Sets New 1-Year Low at $14.56April 20, 2024 | nasdaq.comOversold Conditions For Denali Therapeutics (DNLI)April 19, 2024 | insidertrades.comVicki L. Sato Sells 1,666 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockApril 17, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Director Sells $30,471.14 in StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Vicki L. Sato sold 1,666 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total transaction of $30,471.14. Following the transaction, the director now owns 118,043 shares of the company's stock, valued at approximately $2,159,006.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.April 17, 2024 | msn.comDenali Therapeutics (DNLI) Price Target Decreased by 5.45% to 42.01April 15, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Nisa Investment Advisors LLCNisa Investment Advisors LLC raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 267.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 66,059 shares of the company's stock after acquiriApril 10, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned an average rating of "Buy" from the nine ratings firms that are covering the firm, Marketbeat reports. Nine analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issuedApril 9, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,260,724 shares of the company's stock after selling 420,30April 9, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Price Target Cut to $32.00 by Analysts at UBS GroupUBS Group dropped their price target on shares of Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating on the stock in a research report on Tuesday.April 8, 2024 | tmcnet.comFlagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesApril 3, 2024 | insidertrades.comDenali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes Sells 92,500 SharesApril 2, 2024 | marketbeat.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 92,500 Shares of StockDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Steve E. Krognes sold 92,500 shares of Denali Therapeutics stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the sale, the director now owns 47,341 shares of the company's stock, valued at $970,490.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.March 31, 2024 | marketbeat.comVanguard Group Inc. Buys 354,798 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Vanguard Group Inc. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,597,781 shares of the company's stock after acquirinMarch 22, 2024 | msn.comDenali Therapeutics files to sell 29.29M shares of common stock for holdersMarch 19, 2024 | finance.yahoo.comFurther weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%March 19, 2024 | marketbeat.comZacks Research Comments on Denali Therapeutics Inc.'s FY2026 Earnings (NASDAQ:DNLI)Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at Zacks Research issued their FY2026 EPS estimates for Denali Therapeutics in a research report issued on Monday, March 18th. Zacks Research analyst A. Chakraborty forecasts that the company will post earnings of ($2.71)March 17, 2024 | marketbeat.comWellington Management Group LLP Acquires 250,784 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Wellington Management Group LLP raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,288,960 shares of the company's stock after purchasing an additional 250,784March 17, 2024 | finance.yahoo.comDNLI Apr 2024 12.500 putMarch 16, 2024 | finance.yahoo.comDNLI Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comDNLI Apr 2024 17.500 putMarch 1, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Acquired by Eventide Asset Management LLCEventide Asset Management LLC grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 98.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 621,850 shares of the company's stockMarch 1, 2024 | marketbeat.comDenali Therapeutics Inc. Expected to Post FY2024 Earnings of ($2.70) Per Share (NASDAQ:DNLI)Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, February 28th. HC Wainwright analyst A. Fein now anticipates that the Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Democrats Push to Replace Dollar With Digital Coin, Control Currency. (Ad)Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it. This means you must act NOW before it's too late. DNLI Media Mentions By Week DNLI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNLI News Sentiment▼0.480.54▲Average Medical News Sentiment DNLI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNLI Articles This Week▼333▲DNLI Articles Average Week Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vericel News Today Kymera Therapeutics News Today Twist Bioscience News Today CG Oncology News Today Apogee Therapeutics News Today Sana Biotechnology News Today Recursion Pharmaceuticals News Today Ginkgo Bioworks News Today Arcellx News Today Beam Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNLI) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsObama’s Forever Term [exposed]Porter & CompanyDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis is bad news for Biden…The Freeport SocietyThe 1,000X Crypto PlaybookTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
